Two more biotechs price IPOs, bringing total raise to record heights
Atea Pharmaceuticals and SQZ Biotechnologies have priced their public debuts, adding to this year’s record biotech IPO raise — a pot spilling over $13 billion that dwarfs the total raises of the last four years.
Last Friday, Nasdaq head of healthcare listings Jordan Saxe counted 72 biotech and biopharma IPOs this year, together raising $13.2 billion. He pegged a “fair estimate” of 75 debuts and just under $14 billion in proceeds to round out the year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
